Amy Mullee1,2,3, Niki Dimou3, Marc J Gunter3, Neil Murphy4, Naomi Allen5, Tracy O'Mara6. 1. School of Public Health, Physiotherapy and Sports Science, University College Dublin, Dublin, Ireland. 2. School of Agriculture and Food Science, University College Dublin, Dublin, Ireland. 3. Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France. 4. Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France. murphyn@iarc.fr. 5. Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK. 6. Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Abstract
BACKGROUND: Dysregulation of endocrine pathways related to steroid and growth hormones may modify endometrial cancer risk; however, prospective data on testosterone, sex hormone-binding globulin (SHBG) and insulin-like growth factor (IGF)-1 are limited. To elucidate the role of these hormones in endometrial cancer risk we conducted complementary observational and Mendelian randomization (MR) analyses. METHODS: The observational analyses included 159,702 women (80% postmenopausal) enrolled in the UK Biobank. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models. For MR analyses, genetic variants associated with hormone levels were identified and their association with endometrial cancer (12,906 cases/108,979 controls) was examined using two-sample MR. RESULTS: In the observational analysis, higher circulating concentrations of total (HR per unit inverse normal scale = 1.38, 95% CI = 1.22-1.57) and free testosterone (HR per unit log scale = 2.07, 95% CI = 1.66-2.58) were associated with higher endometrial cancer risk. An inverse association was found for SHBG (HR per unit inverse normal scale = 0.76, 95% CI = 0.67-0.86). Results for testosterone and SHBG were supported by the MR analyses. No association was found between genetically predicted IGF-1 concentration and endometrial cancer risk. CONCLUSIONS: Our results support probable causal associations between circulating concentrations of testosterone and SHBG with endometrial cancer risk.
BACKGROUND: Dysregulation of endocrine pathways related to steroid and growth hormones may modify endometrial cancer risk; however, prospective data on testosterone, sex hormone-binding globulin (SHBG) and insulin-like growth factor (IGF)-1 are limited. To elucidate the role of these hormones in endometrial cancer risk we conducted complementary observational and Mendelian randomization (MR) analyses. METHODS: The observational analyses included 159,702 women (80% postmenopausal) enrolled in the UK Biobank. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models. For MR analyses, genetic variants associated with hormone levels were identified and their association with endometrial cancer (12,906 cases/108,979 controls) was examined using two-sample MR. RESULTS: In the observational analysis, higher circulating concentrations of total (HR per unit inverse normal scale = 1.38, 95% CI = 1.22-1.57) and free testosterone (HR per unit log scale = 2.07, 95% CI = 1.66-2.58) were associated with higher endometrial cancer risk. An inverse association was found for SHBG (HR per unit inverse normal scale = 0.76, 95% CI = 0.67-0.86). Results for testosterone and SHBG were supported by the MR analyses. No association was found between genetically predicted IGF-1 concentration and endometrial cancer risk. CONCLUSIONS: Our results support probable causal associations between circulating concentrations of testosterone and SHBG with endometrial cancer risk.
Authors: Livia S A Augustin; Luigino Dal Maso; Silvia Franceschi; Renato Talamini; Cyril W C Kendall; David J A Jenkins; Ed Vidgen; Carlo La Vecchia Journal: Oncology Date: 2004 Impact factor: 2.935
Authors: Annekatrin Lukanova; Anne Zeleniuch-Jacquotte; Eva Lundin; Andrea Micheli; Alan A Arslan; Sabina Rinaldi; Paola Muti; Per Lenner; Karen L Koenig; Carine Biessy; Vittorio Krogh; Elio Riboli; Roy E Shore; Par Stattin; Franco Berrino; Göran Hallmans; Paolo Toniolo; Rudolf Kaaks Journal: Int J Cancer Date: 2004-01-10 Impact factor: 7.396
Authors: Annekatrin Lukanova; Eva Lundin; Andrea Micheli; Alan Arslan; Pietro Ferrari; Sabina Rinaldi; Vittorio Krogh; Per Lenner; Roy E Shore; Carine Biessy; Paola Muti; Elio Riboli; Karen L Koenig; Mortimer Levitz; Pär Stattin; Franco Berrino; Göran Hallmans; Rudolf Kaaks; Paolo Toniolo; Anne Zeleniuch-Jacquotte Journal: Int J Cancer Date: 2004-01-20 Impact factor: 7.396
Authors: A Zeleniuch-Jacquotte; A Akhmedkhanov; I Kato; K L Koenig; R E Shore; M Y Kim; M Levitz; K R Mittal; U Raju; S Banerjee; P Toniolo Journal: Br J Cancer Date: 2001-04-06 Impact factor: 7.640
Authors: Emma Hazelwood; Eleanor Sanderson; Vanessa Y Tan; Katherine S Ruth; Timothy M Frayling; Niki Dimou; Marc J Gunter; Laure Dossus; Claire Newton; Neil Ryan; Dimitri J Pournaras; Tracy A O'Mara; George Davey Smith; Richard M Martin; James Yarmolinsky Journal: BMC Med Date: 2022-04-19 Impact factor: 11.150